![Guoqing Li](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Guoqing Li
Ventas & Marketing en Golden Maple Leaf Enterprises, Inc. .
Cargos activos de Guoqing Li
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Golden Maple Leaf Enterprises, Inc. | Ventas & Marketing | 27/07/2012 | - |
Corporate Officer/Principal | 23/05/2011 | 27/07/2012 |
Historial de carrera de Guoqing Li
Antiguos cargos conocidos de Guoqing Li.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Director/Miembro de la Junta | 21/10/2010 | 25/12/2012 |
Presidente | 25/12/2012 | 01/01/2016 | |
Independent Dir/Board Member | 23/05/2011 | 01/01/2016 |
Formación de Guoqing Li.
University of International Trade & Finance | Undergraduate Degree |
Estadísticas
Internacional
Canadá | 3 |
China | 2 |
Operativa
Director/Board Member | 1 |
Chairman | 1 |
Independent Dir/Board Member | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Health Technology |
Golden Maple Leaf Enterprises, Inc. |
- Bolsa de valores
- Insiders
- Guoqing Li
- Experiencia